We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Cervical Device Contraception-2 (Nanopaz) (NANOPAZ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00689494
Recruitment Status : Unknown
Verified June 2008 by Bnai Zion Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : June 3, 2008
Last Update Posted : June 3, 2008
Information provided by:
Bnai Zion Medical Center

Brief Summary:
Measure blood progesterone by using cervical device contraception.

Condition or disease Intervention/treatment Phase
Healthy Other: Nanopaz contraception device Phase 1 Phase 2

Detailed Description:

A very small cervical device that releases small amount of progesterone 20 mcgm/day.

The target of the research is to measure blood progesterone by using the cervical device.

This small device delivers progesterone by nanotechnology method.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Cervical Device Contraception
Study Start Date : June 2008
Estimated Primary Completion Date : December 2008
Estimated Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Birth Control
U.S. FDA Resources

Intervention Details:
    Other: Nanopaz contraception device
    levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy method
    Other Name: levonorgestrel device for cervical contraception-nantechnolgy method

Primary Outcome Measures :
  1. blood progesterone measure in blood [ Time Frame: one to two months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   1 Month to 2 Months   (Child)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 10 healthy women are candidate for hysterectomy

Exclusion Criteria:

  • Women with neoplastic malignancy disease or thrombophylia

Responsible Party: Baram Paz, Bnai Zion MC
ClinicalTrials.gov Identifier: NCT00689494     History of Changes
Other Study ID Numbers: BnaiZionMC-08-BP-003-CTIL
First Posted: June 3, 2008    Key Record Dates
Last Update Posted: June 3, 2008
Last Verified: June 2008

Keywords provided by Bnai Zion Medical Center:
Nanopaz device
Blood progesterone measure in using the device
Delivery progesterone
Progesterone levonorgestrel

Additional relevant MeSH terms:
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Contraceptives, Oral, Synthetic
Contraceptives, Oral